What is Akadeum Life Sciences?
Headquartered in Ann Arbor, Michigan, Akadeum Life Sciences is a pioneer in the development of Buoyancy Activated Cell Sorting (BACS) technology. By utilizing a novel floatation-based target isolation platform, the company provides researchers and clinicians with a more efficient, scalable method for sample preparation. Beyond its research-use-only product portfolio, Akadeum is actively cultivating business-to-business partnerships to integrate its isolation solutions into broader diagnostic and bioprocessing ecosystems, effectively bridging the gap between laboratory innovation and clinical application.
How much funding has Akadeum Life Sciences raised?
Akadeum Life Sciences has raised a total of $47.5M across 7 funding rounds:
Private Equity
$905K
Angel/Seed
$1M
Private Equity
$1.5M
Other Financing Round
$4.5M
Series B
$17.5M
Other Financing Round
$20M
Stock/Share Issuance
$2.1M
Private Equity (2015): $905K, investors not publicly disclosed
Angel/Seed (2015): $1M led by Invest Michigan, Michigan eLab, and Invest Detroit
Private Equity (2017): $1.5M, investors not publicly disclosed
Other Financing Round (2019): $4.5M featuring University of Michigan MINTS and Berkeley Catalyst Fund
Series B (2021): $17.5M backed by Beringea, BlueStone Venture Partners, Arboretum Ventures, Agilent Technologies, and Lifespan Ventures
Other Financing Round (2025): $20M with participation from Arboretum Ventures, Michigan Capital Network, and NYBC Ventures
Stock/Share Issuance (2026): $2.1M, investors not publicly disclosed
Key Investors in Akadeum Life Sciences
Arboretum Ventures
A Midwest-based healthcare venture capital firm with over two decades of experience, focusing on early-stage startups in under-ventured markets to improve patient outcomes.
NYBC Ventures
An early-stage life sciences investment fund launched by the New York Blood Center, specializing in breakthroughs in cellular therapies, hematology, and regenerative medicine.
Beringea
An international venture capital firm that invests in high-growth businesses across the US and UK, providing strategic support to help entrepreneurs build industry-leading companies.
What's next for Akadeum Life Sciences?
With the successful closure of its most recent financing round, Akadeum Life Sciences is well-positioned to accelerate its commercial expansion and deepen its penetration into the cell therapy and bioprocessing markets. The company's strategic roadmap likely involves scaling manufacturing capabilities to meet rising demand for its BACS kits while simultaneously advancing its B2B partnership pipeline. As the firm transitions into a more mature growth phase, the focus will remain on leveraging its unique buoyancy-based platform to set new standards for purity and yield in cellular isolation, ultimately driving long-term value for its diverse base of institutional backers and healthcare stakeholders.
See full Akadeum Life Sciences company page
